Holen Sie sich die Stockscreener-App
18.19
1.34%
0.24
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment - Insider Monkey
Clearbridge Investments LLC Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Cibc World Market Inc. Takes Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne therapeutics director Brian Posner buys $33,880 in stock By Investing.com - Investing.com Canada
Dyne therapeutics director Brian Posner buys $33,880 in stock - Investing.com
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) receives 35,152 stock options - Stock Titan
Director Lubner gets 35,152 Dyne (DYN) options at $17.04 strike - Stock Titan
Dyne Therapeutics director granted 35,152 options | DYN Insider Trading - Stock Titan
Director at Dyne Therapeutics (NASDAQ: DYN) granted 35,152 stock options at $17.04 - Stock Titan
Director at Dyne Therapeutics (DYN) receives grant of 35,152 stock options - Stock Titan
Dyne Therapeutics (DYN) director buys stock and receives 35,152-share option grant - Stock Titan
Dyne Therapeutics (DYN) investors double share authorization and approve all proposals - Stock Titan
Dyne spikes as late-stage trial for Duchenne therapy gets underway - MSN
Dyne Therapeutics (DYN) director Brian Posner buys 2,500 shares in open market - Stock Titan
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone - Insider Monkey
Dyne Therapeutics DM1 Trial Reaches Pivotal Stage With ACHIEVE Enrollment - Sahm
A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment Milestone - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Evercore Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $47 - Moomoo
Dyne Therapeutics (DYN) Completes Enrollment in Phase 1/2 ACHIEVE Trial - GuruFocus
How Dyne Therapeutics Inc. (DYN) Affects Rotational Strategy Timing - Stock Traders Daily
Dyne Therapeutics stock hits 52-week low at 17.54 USD By Investing.com - Investing.com Australia
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 - Investing News Network
DYN: BLA filed for DMD, DM1 trial fully enrolled, and robust pipeline advances with strong financials - TradingView
Dyne completes enrollment in DM1 therapy trial expansion cohort By Investing.com - Investing.com Australia
Dyne Fully Enrolls ACHIEVE Trial for DM1 Therapy - TipRanks
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) - The Manila Times
Dyne completes enrollment of 71-patient ACHIEVE registrational cohort; topline data due Q1 2027 - TradingView
Dyne Therapeutics (Nasdaq: DYN) hits key ACHIEVE trial enrollment milestone - Stock Titan
Experimental DM1 drug hits key trial milestone, Dyne eyes 2028 US launch - Stock Titan
Dyne Therapeutics stock hits 52-week low at 17.54 USD - Investing.com
DYN stock gains as it gears up for accelerated approval of DMD therapy: Wall Street sees 140% upside - MSN
Dyne Therapeutics stock gains 4.5% after BLA filing for DMD therapy - MSN
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean - The Motley Fool
Dyne Therapeutics (DYN) Is Up 11.3% After FDA BLA Filing For DMD Drug Candidate Zeleciment Rostudirsen - Sahm
Dyne therapeutics director Brian Posner buys $36,420 in stock By Investing.com - Investing.com Australia
Dyne therapeutics director Brian Posner buys $36,420 in stock - Investing.com
Dyne Therapeutics (DYN) director Brian Posner buys 2,000 shares in open market - Stock Titan
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy - Yahoo Finance
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $47 - Moomoo
Dyne Therapeutics (DYN) Surges 5.87% as Biotech Momentum BuildsLow Volatility Picks - The Legal Advocate
Dyne Therapeutics (DYN) Seeks FDA Approval for Duchenne Muscular Dystrophy Treatment - GuruFocus
Dyne Therapeutics Announces Submission of Biologics License Application to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy - Investing News Network
Dyne submits biologics license application for DMD treatment - Investing.com
1.04%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):